Highest-materiality recent filing
Lixte completes merger with NOMAD, changes name to Nomad Power Solutions, ticker to NMAD
Merger closed July 1, 2026; NOMAD becomes wholly owned subsidiary of Lixte.
Lixte issues $6.5M secured note to NOMAD for pending merger
Issued $6.5M secured promissory note to NOMAD in connection with pending merger.
Lixte Biotechnology to acquire NOMAD Transportable Power Systems, pivoting to energy storage
Consideration: up to 50,500 Series D Convertible Preferred shares ($1,000/sh, convertible at $1.00) plus up to 3M common shares.
Lixte Biotechnology closes ~$16.6M registered direct offering of common stock and warrants
Gross proceeds of ~$16.6 million from sale of 2,625,362 shares and pre-funded warrants.
Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board
Company will seek strategic acquisition partner for clinical-stage pharma/med-tech operations.
CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.
Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake
Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).
Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026
Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.
Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement
Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).
Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
LIXTE makes $2.6M initial cryptocurrency purchase to diversify treasury
Purchased 10.5 Bitcoin and 300 Ethereum for total of $2.6 million.
Lixte appoints new CFO, two board members; relocates HQ to Boca Raton
Rene Bernards, Regina Brown, Bas van der Baan resigned from Board; CFO Robert Weingarten resigned; all departures amicable.
LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance
Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.
Lixte appoints two new independent directors; CMO resigns effective July 31
Board adds Jason Sawyer and Dr. Michael Holloway as independent directors, designated by Series B Preferred Stock holders.
LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise
Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers
Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.
Lixte Biotechnology closes $1.5M registered direct offering of common stock and pre-funded warrants
Closed registered direct offering of 974,026 shares (or pre-funded warrants) at $1.54 per share for gross proceeds of ~$1.5M.
Lixte closes $5.0M private placement of common stock, preferred and warrants
Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.
Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3
Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.
Nasdaq Panel grants Lixte extension to July 3, 2025 for equity compliance
Lixte received extension from Nasdaq Hearings Panel after April 3 hearing on equity deficiency.
LIXTE updates LB-100 clinical progress; two new trials started, $1.05M offering completed
First patient dosed in Phase 1b/2 trial combining LB-100 with GSK's dostarlimab for ovarian clear cell carcinoma.
Lixte Biotechnology relieved of $3.1M funding obligation for Phase 2 sarcoma study
Amendment No. 1 to clinical trial agreement with GEIS relieves Lixte of approx $3,095,000 obligation for randomized Phase 2 portion.
Lurie Cancer Center (Northwestern University) opened as second clinical site for LB-100 plus GSK's Dostarlimab.
Lixte Biotechnology fails Nasdaq equity minimum; plans appeal to avoid delisting
Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Feb 18, 2025 extension deadline.
Lixte Biotechnology enters $1.7M at-the-market sales agreement with WallachBeth Capital
Entered ATM sales agreement to sell up to $1.7M of common stock.
Lixte Biotechnology gets Nasdaq extension to Feb 18, 2025 to meet equity requirement
Nasdaq notified non-compliance with $2.5M minimum stockholders' equity requirement.
LIXTE receives USPTO Notice of Allowance for patent covering LB-100 with cancer immunotherapies
U.S. Patent application 16/467,721 titled 'Oxabicycloheptanes for Modulation of Immune Response' allowed.
Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support
Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.
Lixte Biotechnology receives Nasdaq deficiency notice for stockholders' equity requirement
Received Notice from Nasdaq on August 19, 2024 for non-compliance with Listing Rule 5550(b)(1) requiring minimum $2,500,000 stockholders' equity.
LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination
New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.
Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI
Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.
Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.
Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024
Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.
On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.
Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer
effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company’s Chief Medical Officer.
Effective September 26, 2023, the Company appointed John S. Kovach, M.D. as Executive Chairman. Dr. Kovach will no longer act as the Company’s President and Chief Executive Officer, but will continue as the Company’s Chief Scientific Officer.
Promoted Eric Forman, the Company’s Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year.
Effective as of June 17, 2022, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc. (the “Company”) appointed Bastiaan van der Baan to the Board as an independent director.
Effective as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board as an independent director.
On May 9, 2022, Philip Palmedo informed the Company that he did not intend to stand for reelection at the next Annual Meeting of Stockholders of the Company.
Max materiality 0.90 · Median 0.60 · Most common event other_material